Protocol Ledger

NCT07595549 · Phase III · RECRUITING

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Interventional Phase III clinical trial protocol NCT07595549 sponsored by Pfizer in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-10 Enrollment: 954 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07595549
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)954 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07595549
Protocol FieldVerified Registry Value
NCT IdentifierNCT07595549
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment954 participants (ESTIMATED)
Registered Start Date2026-06-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07595549
Hospital Research SiteLocationSite Profile
Diablo Clinical Research IncWalnut Creek, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI